Group 1 - The company expects its operating revenue for 2025 to be between 550 million and 600 million yuan, with a net profit attributable to shareholders projected to be between -25 million and -30 million yuan, and the net profit after deducting non-recurring gains and losses also expected to be between -25 million and -30 million yuan [1] - The chain pharmacy industry is facing a decline in performance due to changes in the macro market environment, increased competition, industry policy adjustments, and shifts in consumer habits [1] - The actual operating performance of the acquired subsidiaries did not meet expectations due to the aforementioned industry environment, operational issues, and business integration challenges, leading the company to conduct impairment tests on goodwill and recognize significant impairment losses, which notably impacted current profits [1]
达嘉维康(301126.SZ)：预计2025年净亏损2.5亿元~3亿元